ABIONYX Pharma S.A.
ABNX.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | €42 | €41 | €38 | €40 |
| - Cash | €3 | €3 | €5 | €4 |
| + Debt | €4 | €3 | €3 | €3 |
| Enterprise Value | €43 | €41 | €36 | €39 |
| Revenue | €2 | €2 | €2 | €3 |
| % Growth | -6% | -3.8% | -6.7% | – |
| Gross Profit | €0 | €1 | €0 | €1 |
| % Margin | 10.8% | 26.5% | 12.9% | 25% |
| EBITDA | -€2 | €2 | -€2 | -€1 |
| % Margin | -107.4% | 90.9% | -97.7% | -45.3% |
| Net Income | -€2 | -€2 | -€2 | -€1 |
| % Margin | -108.5% | -101.6% | -89.1% | -50.6% |
| EPS Diluted | -0.067 | -0.066 | -0.065 | -0.041 |
| % Growth | -0.6% | -2% | -59.2% | – |
| Operating Cash Flow | -€2 | -€2 | -€2 | -€1 |
| Capital Expenditures | -€0 | €0 | -€0 | -€0 |
| Free Cash Flow | -€2 | -€2 | -€2 | -€1 |